New Alzheimer’s Drug Leqembi Gets Full FDA Approval
He Food and Drug Administration on Thursday fully approved the Alzheimer's drug Leqembi, amid concerns about its safety, cost and accessibility. The move marks the first time that a drug intended to slow the progression of the disease has gained full regulatory approval. Other approved drugs only target your symptoms."I don't think we can underestimate the importance of this moment," said Donna Wilcock, associate dean for biomedicine at the University of Kentucky. About 6.7 million adults 65 and older in the United States have Alzheimer's disease, according to the Alzheimer's Association. Leqembi, from Japanese drugmaker Eisai and US-based drugmaker Biogen,…
